Catalyst Pharmaceutical Partners Aktie
27,60
EUR
+0,10
EUR
+0,36
%
31,46
USD
+0,02
USD
+0,06
%
Catalyst Pharmaceutical Partners jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Catalyst Pharmaceutical Partners Aktie Analyse
| 21.09.18 | Catalyst Pharmaceutical Partners Overweight | Cantor Fitzgerald | |
| 30.09.14 | Catalyst Pharmaceutical Partners Buy | ROTH Capital Partners, LLC | |
| 14.11.12 | Catalyst Pharmaceutical Partners buy | ROTH Capital Partners, LLC | |
| 29.11.07 | Catalyst Pharmaceutical Partners market outperform | Rodman & Renshaw |
Werbung
Werbung